Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases

Carcinogenesis

Volumn 20, Issue 6, 1999, Pages 991-995

  Ozawa, Shogo ^a,d   Schoket, Bernadette ^b   McDaniel, L Patrice ^a   Tang, Yong Ming ^a   Ambrosone, Christine B ^a   Kostic, Szilárd ^c   Vincze, István ^b   Kadlubar, Fred F ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH   (Hungary)

^c NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^d NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GLUTATHIONE TRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGED; ARTICLE; BRONCHUS; CODON; DNA ADDUCT; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUNGARY; LUNG CANCER; LUNG DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SMOKING;

ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; BRONCHI; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; DNA PRIMERS; GLUTATHIONE TRANSFERASE; HUMANS; HUNGARY; LUNG DISEASES; NAD(P)H DEHYDROGENASE (QUINONE); STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0033018006     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.6.991     Document Type: Article

References (44)

1. IARC (1986) Tobacco Smoking, IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans No. 39. IARC, Lyon.
2. Doll, R. and Peto,R. (1978) Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and life-time nonsmokers. J. Epidemiol. Community Health, 32, 303-313.
3. Moolgavkar, S.H., Dewanji, A. and Leubeck, G. (1989) Cigarette smoking and lung cancer: reanalysis of the British doctors' data. J. Natl Cancer Inst., 81, 415-420.
4. Crawford, F.G., Mayer, J., Santella, R.M., Cooper, T.B., Ottman, R., Tsai, W,-Y., Simon-Cereijido, G., Wang, M., Tang, D. and Perera, J.P. (1994) Biomarkers of environmental tobacco smoke in preschool children and their mothers. J. Natl Cancer Inst., 86, 1398-1402.
5. Hammond, S.K., Coghlin, J., Gann, P.H., Paul, M., Taghizadeh, K., Skipper, P.L. and Tannenbaum, S.R. (1993) Relationship between environmental tobacco smoke exposure and carcinogen-hemoglobin adduct levels in nonsmokers. J. Natl Cancer Inst., 85, 474-478.
6. 32P-analysis of cigarette smoke-induced DNA damage in human tissues and mouse skin. Cancer Res., 46, 5869-5877.
7. Phillips, D.H., Hewer, A., Martin, C.N., Garner, R.C. and King, M.M. (1988) Correlation of DNA adduct levels in human lung with cigarette smoking. Nature (Lond.), 336, 790-792.
8. Alexandrov, K., Rojas, M., Kadlubar, F.F., Lang, N.P. and Bartsch, H. (1996) Evidence of anti-benzo[a]pyrene diolepoxide-DNA adduct formation in human colon mucosa. Carcinogenesis, 17, 2081-2083.
9. Shimada, T., Martin, M.V., Pruess-Schwartz, D., Marnett, L.J. and Guengerich, F.P. (1989) Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res., 49, 6304-6312.
10. Roberts-Thomson, S.J., McManus, M.E., Tukey, R.H., Gonzalez, F.J. and Holder, G.M. (1993) The catalytic activity of four expressed human cytochrome P450s towards benzo[a]pyrene and the isomers of its proximate carcinogen. Biochem. Biophys. Res. Commun., 192, 1373-1379.
11. Yun, C.-H., Shimada, T. and Guengerich, F.P. (1992) Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Cancer Res., 52, 1868-1874.
12. Degawa, M., Stern, S.J., Martin, M.V., Guengerich, F.P., Fu, P.P., Ilett, K.F., Kaderlik, K.R. and Kadlubar, F.F. (1994) Metabolic activation and carcinogen-DNA adduct detection in human larynx. Cancer Res., 54, 4915-4919.
13. Ketterer, B., Harris, J.M., Talaska, G., Meyer, D.J., Pemble, S.E., Taylor, J.B., Lang, N.P. and Kadlubar, F.F. (1992) The human glutathione S-transferase supergene family, its polymorphism and its effects on susceptibility to lung cancer. Environ. Health Perspect., 98, 87-94.
14. Cadenas, E. (1995) Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem. Pharmacol., 49, 127-140.
15. Joseph, P. and Jaiswal, A.K. (1994) NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P450IA1 and P450 reductase. Proc. Natl Acad. Sci. USA, 91, 8413-8417.
16. Kawajiri, K., Nakachi, K., Imai, K., Yoshii, A., Shinoda, N. and Watanabe, J. (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett., 263, 131-133.
17. Hayashi, S.-I., Watanabe, J., Nakachi, K. and Kawajiri, K. (1991) Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J. Biochem., 110, 407-411.
18. Stubbins, M.J., Harries, L.W., Smith, G., Tarbit, M.H. and Wolf, C.R. (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics, 6, 429-439.
19. Harries, L.W., Stubbins, M.J., Forman, D., Howard, G.C. and Wolf, C.R. (1997) Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis, 18, 641-644.
20. Rosvald, E.A., McGlynn, K.A., Lustbader, E.D. and Buetow, K.H. (1995) Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199-206.
21. Nakachi, K., Imai, K., Hayashi, S.-I. and Kawajiri, K. (1993) Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res., 53, 2994-2999.
22. Okada, T., Kawashima, K., Fukushi, S., Minakuchi, T. and Nishimura, S. (1994) Association between a cytochrome P450 CYP1A1 genotype and incidence of lung cancer. Pharmacogenetics, 4, 333-340.
23. Sugimura, H., Hamada, G.S., Suzuki, I., Iwase, T., Kiyokawa, E., Kino, I. and Tsugane, S. (1995) CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil. Pharmacogenetics, 5, S145-S148.
24. Ryberg, D., Skaug, V., Hewer, A., Phillips, D.H., Harries, L.W., Wolf, C.R., Øgreid, D., Ulvik, A., Vu, P. and Haugen, A. (1997) Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis, 18, 1285-1289.
25. London, S.J., Daly, A.K., Leathart, J.B.S., Navidi, W.C. and Idle, J.R. (1996) Lung cancer risk in relation to the CYP2C9* 11CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics, 6, 527-533.
26. London, S.J., Sullivan-Klose, T., Daly, A.K. and Idle, J.R. (1997) Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics, 7, 401-404.
27. Wiencke, J.K., Spitz, M.R., McMillan, A. and Kelsey, K.T. (1997) Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol. Biomarkers Prev., 6, 87-92.
28. Schoket, B., Phillips, D.H., Kostic, S. and Vincze, I. (1998) Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 MspI and GSTM1 genotypes in lung patients. Carcinogenesis, 19, 841-846.
29. Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F.J. and Idle, J.R. (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics, 5, 389-392.
30. Wang, S.-L., Huang, J., Lai, M.-D. and Tsai, J.-J. (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics, 5, 37-42.
31. Shou, M., Korzekwa, K.R., Crespi, C.L., Gonzalez, F.J. and Gelboin, H.V. (1994) The role of 12 cDNA-expressed human, rodent and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol. Carcinog., 10, 159-168.
32. Bauer, E., Guo, Z., Ueng, Y.-F., Bell, L.C., Zeldin, D. and Guengerich, F.P. (1995) Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol., 8, 136-142.
33. Gautier, J.-C., Lecoeur, S., Cosme, J., Perret, A., Urban, P., Beaune, P. and Pompon, D. (1996) Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism, as predicted from heterologous expression in yeast. Pharmacogenetics, 6, 489-499.
34. Shimada, T., Yun, C.-H., Yamazaki, H., Gautier, J.-C., Beaune, P.H. and Guengerich, F.P. (1992) Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol. Pharmacol., 41, 856-864.
35. Shimada, T., Yamazaki, H., Mimura, M., Wakamiya, N., Ueng,Y.-F., Guengerich, F.P. and Inui, Y. (1996) Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs. Drug Metab. Dispos., 24, 515-522.
36. Alexandrov, K, Rojas.M., Geneste, O., Castegnaro, M., Camus, A.-M., Petruzzelli, S., Giuntini, C. and Bartsch, H. ( 1992) An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res., 52, 6248-6253.
37. Rojas, M., Alexandrov, K., Auburtin, G., Wastiaux-Denamur, A., Mayer, L., Mahieu, B., Sebastien, P. and Bartsch, H. (1995) Anti-benzo[a]pyrene diolepoxide-DNA adduct levels in peripheral mononuclear cells from coke oven workers and the enhancing effect of smoking. Carcinogenesis, 16, 1373-1376.
38. Ross, J., Nelson, G., Kligerman, A., Erexson, G., Bryant, M., Earley, K., Gupta, R. and Nesnow, S. (1990) Formation and persistence of novel benzo(a)pyrene adducts in rat lung, liver and peripheral blood lymphocyte DNA. Cancer Res., 50, 5088-5094.
39. Rettie, A.E., Wienkers, L.C., Gonzalez, F.J., Trager, W.F. and Korzekwa,K.R. (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39-42.
40. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6, 341-349.
41. Hashimoto, Y, Otsuki, Y., Odani, A., Takano, M., Hattori, H., Furusho, K. and Inui, K.-I. (1996) Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol. Pharm. Bull., 19, H03-1105.
42. Bhasker, C.R., Miners, J.O., Coulter, S. and Birkett, D.J. (1997) Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics, 7, 51-58.
43. Zimniak, P., Nanduri, B., Pikula, S., Bandorowicz-Pikula, J., Singhal, S.S., Srivastava, S.K., Awasthi, S. and Awasthi, Y.C. (1994) Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur. J. Biochem., 224, 893-899.
44. Traver, R.D., Horikoshi, T., Danenberg, K.D., Stadlbauer, T.H.W., Danenberg, P.V., Ross, D. and Gibson, N.W. (1992) NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res., 52, 797-802.